However, to date, there have been no large randomized controlled trials (RCTs) comparing the efficacy of lorlatinib with that of alectinib, currently positioned as first-line therapy in patients with ALK-inhibitor-naïve NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.